SCN8A: A Promising Drug Target and Biofilm Marker for the Treatment of Chronic Obstructive Pulmonary Disease

Target Name: SCN8A

NCBI ID: G6334

SCN8A

SCN8A: A Promising Drug Target and Biofilm Marker for the Treatment of Chronic Obstructive Pulmonary Disease

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, representing a significant public health burden. The molecular mechanisms underlying COPD pathogenesis are not well understood, but it is known that COPD is associated with chronic inflammation, oxidative stress, and metabolic dysregulation. One of the key players in this process is the sodium channel subfamily 8 (SCN8A), which has been shown to play a crucial role in respiratory diseases. In this article, we review the current literature on SCN8A, including its function in COPD, its potential as a drug target, and its role as a biomarker for the diagnosis and treatment of COPD.

Introduction:

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that is characterized by progressive airflow limitation, coughing, and wheezing. It is a leading cause of morbidity and mortality worldwide, and its incidence is expected to increase in the coming years due to the increasing burden of the lifestyle diseases. The underlying molecular mechanisms underlying COPD pathogenesis are not well understood, but it is known that COPD is associated with chronic inflammation, oxidative stress, and metabolic dysregulation.

SCN8A: A Key Player in COPD Pathogenesis

The sodium channel subfamily 8 (SCN8A) is a family of transmembrane proteins that play a crucial role in various physiological processes, including cell signaling, neurotransmission, and inflammation. It is characterized by the presence of a unique voltage-dependent channel that is responsible for the rapid depolarization of the plasma membrane during the initiation of an action potential.

In the context of COPD, SCN8A has been shown to play a key role in the regulation of respiratory muscle contractions and the maintenance of normal lung function. Studies have shown that SCN8A is involved in the regulation of the contractions of smooth muscle in the airways, which are critical for airflow. Additionally, SCN8A has been shown to play a role in the regulation of surfactant production and the formation of surfactant granules in the airways, which are important for reducing surface tension and promoting gas exchange.

Molecular Mechanisms:

The role of SCN8A in COPD pathogenesis is not well understood, but it is known that SCN8A is involved in the regulation of various cellular processes that are critical for the development and progression of COPD. Chronic exposure to environmental irritants, such as pollution, is associated with increased expression of SCN8A, which may contribute to the development of COPD.

Drug Targets:

SCN8A is a drug target of interest for the treatment of COPD due to its involvement in the regulation of respiratory muscle contractions and the maintenance of normal lung function. Several studies have shown that inhibitors of SCN8A have the potential to improve lung function and reduce airflow obstruction in individuals with COPD.

Biomarkers:

SCN8A has also been shown to be a potential biomarker for the diagnosis and treatment of COPD. Studies have shown that SCN8A levels are elevated in individuals with COPD, and that these levels can be reduced by treatment with COPD simulator devices or by exposure to environmental irritants. Additionally, studies have shown that SCN8A levels are associated with various markers of chronic inflammation, oxidative stress, and metabolic dysregulation, which are also associated with the development and progression of COPD.

Conclusion:

In conclusion, SCN8A is a protein that plays a crucial role in the regulation of various cellular processes that are critical for the development and progression of COPD. Its involvement in the regulation of respiratory muscle contractions and the maintenance of normal lung function makes it an attractive drug target for the treatment of COPD. Furthermore, its potential as a biomarker for the diagnosis and treatment of COPD makes it an important target for future research.

Protein Name: Sodium Voltage-gated Channel Alpha Subunit 8

Functions: Mediates the voltage-dependent sodium ion permeability of excitable membranes (PubMed:29726066). Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient

The "SCN8A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCN8A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets